COVID-19 Outbreak-Global Eye Infection Drugs Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020
By Maia Research | Pharmaceuticals and Healthcare | Aug 2020 | Page 126
The Eye Infection Drugs market revenue was xx.xx Million USD in 2019, and will reach xx.xx Million USD in 2025, with a CAGR of x.x% during 2020-2025. Under COVID-19 outbreak globally,....
COVID-19 Outbreak-Global Tuberculosis Diagnosis and Treatment Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020
By Maia Research | Pharmaceuticals and Healthcare | Aug 2020 | Page 103
The Tuberculosis Diagnosis and Treatment market revenue was xx.xx Million USD in 2019, and will reach xx.xx Million USD in 2025, with a CAGR of x.x% during 2020-2025. Under COVID-19 outbreak....
COVID-19 Outbreak-Global Biotech, Pharma and Health Care Automation Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020
By Maia Research | Pharmaceuticals and Healthcare | Aug 2020 | Page 106
The Biotech, Pharma and Health Care Automation market revenue was xx.xx Million USD in 2019, and will reach xx.xx Million USD in 2025, with a CAGR of x.x% during 2020-2025. Under....
COVID-19 Outbreak-Global Lenalidomide Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020
By Maia Research | Pharmaceuticals and Healthcare | Aug 2020 | Page 111
Lenalidomide (trade name Revlimid) is a derivative of thalidomide approved by FDA in 2005.It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic....
COVID-19 Outbreak-Global Fabrazyme-Drug Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020
By Maia Research | Pharmaceuticals and Healthcare | Aug 2020 | Page 115
Fabrazyme (agalsidase beta) is a man-made form of the naturally-occurring alpha-galactosidase A enzyme. A deficiency of this enzyme is called Fabry disease. Agalsidase beta reduces deposits of globotriaosylceramide (GL-3) in....